Bexmarilimab with azacitidine for higher-risk myelodysplastic syndromes
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding bexmarilimab to standard azacitidine treatment helps people with higher-risk myelodysplastic syndromes (MDS), a type of blood cancer. It compares this combination to azacitidine plus a placebo to see which is more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been newly diagnosed with higher-risk myelodysplastic syndromes (MDS) and have not yet had treatment for it.
- You are considered able to receive azacitidine as part of your care.
- You are generally able to care for yourself (score 0 to 2 on a standard performance scale).
- Your blood counts and organ function (kidneys, liver) meet certain levels.
- You are not planning to have a stem cell transplant right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, AK117, combined with azacitidine for people newly diagnosed with high-risk myelodysplastic syndromes (MDS), a blood disorder. The goal is to see if the combination can help improve outcomes.
This trial tests a new oral medication (iadademstat) combined with a standard therapy called a hypomethylating agent for people with higher-risk myelodysplastic syndromes (MDS) or related blood cancers. The goal is to see if the combination is safe and effective.
This study tests a combination of two drugs, azacitidine and rotercept, for people with a type of blood cancer called myelodysplastic syndrome (MDS) that has a higher risk of progressing. The goal is to see if adding rotercept helps control the disease better than standard care.
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
This study tests an investigational oral liquid called BLEX 404 taken together with a standard drug, azacitidine, for people with higher-risk MDS or CMML. It aims to see if the combination is safe and effective.
This Phase 3 trial tests whether doing an “allogeneic” stem cell transplant works best for people newly diagnosed with higher-risk MDS (a bone marrow disorder). It’s mainly for patients who are healthy enough to receive a transplant and haven’t started MDS treatment yet.
Hear when a new Higher-risk Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.